Pharmahungary Group participates in ambitious EU EVEREST Project 

Although the initial budget of the EU EVEREST project is small, its impact could be huge. Extracellular vesicles enclose DNAs, RNAs, lipids, and proteins triggering specific cell anwers in a cell-to-cell communication process and are thus of high interest for ultra-targeted therapies. Coordinated by Professor Breandán Kennedy, UCD School of Biomolecular and Biomedical Science in Dublin, the €1.3m research project brings together 21 institutions from 11 countries standardise methods for isolating and characterising these vesicles, facilitating their use to improve the precision and effectiveness of treatments for complex diseases such as cancer and cardiovascular conditions. The project, funded through the Marie Skłodowska-Curie Actions (MSCA) programme under Horizon Europe GA101183034, will run for 48 months, starting in January 2025.

Professor Péter Ferdinandy, MD, PhD, MBA, the Founder & CEO of Pharmahungary Group, highly-cited researcher, expressed his enthusiasm, which loabs are located in Semmelweis University, Budapest, Hungary and University of Szeged, Szeged, commented: “We are proud to support the goals of EVEREST as it represents a bold step forward in the quest for innovative medical solutions. Since its foundation in 2001, Pharmahungary Group core expertise is cardiovascular drug development including miRNA therapies, an especially current field as the Nobel Prize in Physiology or Medicine was awarded in 2024 for the discovery of miRNAs. We also have over a decade of experience with extracellular vesicles research evidenced by several scientific publications and an SME Instrument Champion title received for our extracellular vesicle isolation platform called Vezics.”

The EVEREST consortium unites top academic and non-academic partners across Europe. Academic members include University College Dublin (Ireland), Trinity College Dublin (Ireland), University of Vigo (Spain), Universidade Nova de Lisboa (Portugal), Luxembourg Institute of Science and Technology (Luxembourg), Justus-Liebig University Giessen (Germany), South East Technological University (Ireland), Linköping University (Sweden), Comenius University Bratislava (Slovakia), Queen’s University Belfast (UK), State Research Institute Centre for Innovative Medicine (Lithuania), and Fundación Progreso y Salud GENYO (Spain). Non-academic partners include SiriusXT (Ireland), Bioreperia (Sweden), Fox Biosystems (Belgium), Pharmahungary (Hungary), Acousort AB (Sweden), Mursla (UK), Xenopat (Spain), De Rotos y Descosidos (Spain), and Vesiculab Ltd (UK). This multidisciplinary and cross-sector approach enables the project to cover everything from basic research to commercialapplication, maximising the impact of scientific advances on clinical and societal outcomes.